S&P 500, Nasdaq 100, and Dow futures edge higher as traders await key employment data amid geopolitical risks. U.S. stock index futures climbed early Friday, shrugging off elevated U.S.-Iran tensions as investors focused on the upcoming April jobs report. S&P 500 futures g
The apparel company now forecasts 14%-16% net revenue growth for 2026 following a 28% year-over-year increase in Q1. FIGS Inc. revised its 2026 net revenue growth forecast to 14%-16% after reporting a 28% year-over-year increase in Q1 2026. The company attributed the outpe
The firm revised its full-year guidance upward after Q1 2026 performance exceeded prior expectations. Abacus Global Management raised its adjusted net income outlook for FY2026 to a range of $100M-$106M, up from $96 million-$104 million. The revision reflects stronger-than
The fertility benefits manager raised its full-year guidance after reporting Q1 2026 results, signaling stronger demand. Progyny updated its 2026 financial outlook, projecting revenue between $1.365 billion and $1.405 billion, up from prior expectations. Adjusted EBITDA is
The healthcare firm projects 2026 revenue between $3.8 billion and $4.1 billion while targeting net leverage at or below 2x. Astrana Health outlined a 2026 revenue outlook of $3.8 billion to $4.1 billion, citing strong Q1 2026 performance. The company attributed growth to
MercadoLibre reports its fastest revenue growth since Q2 2025 as spending on expansion accelerates. MercadoLibre posted a 49% year-over-year rise in Q1 2026 net revenue, marking its strongest growth rate in nearly a year. The company attributed the gain to aggressive inves
The company advances its Project New Horizon pilot while broadening its 0- to 24-hour energy storage solutions in Q1 2026. ESS Tech, Inc. (GWH) announced plans to deliver its 5-MW/50-MWh Project New Horizon pilot by December 2027, marking a key milestone in its energy stor
Xenon Pharmaceuticals targets a Q3 2026 NDA submission for AZK, with commercial launch planned for late 2027 or early 2028. Xenon Pharmaceuticals announced plans to file a New Drug Application for AZK in Q3 2026, positioning the therapy for a potential commercial launch in
Eastman Kodak reports $15M in operational EBITDA for Q1 2026, marking three consecutive quarters of year-over-year growth. Eastman Kodak posted a 7% year-over-year increase in Q1 2026 revenue, reaching $265M, while operational EBITDA hit $15M. The company attributed the ga
Commerzbank AG press release (CRZBF): Q1 GAAP EPS of â¬0.84. - Net interest income of â¬2.05B (-1.0% Y/Y). - The Common Equity Tier 1 ratio was 14.5% as at 31 March 2026, compared with 14.7% as at year-end 2025. - The leverage ratio was 4.3%, on a par with the end of 2025
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.